Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma.
HPV
oropharynx
second primary
squamous cell carcinoma
transoral surgery
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
08
12
2021
received:
03
06
2021
accepted:
01
02
2022
pubmed:
18
2
2022
medline:
8
4
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Little data exists regarding the incidence of oropharyngeal and upper aerodigestive tract (UADT) second primary malignancies (SPM) among human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here we evaluate SPM rates among patients with HPV-related OPSCC. A retrospective cohort study of 412 patients with HPV-related OPSCC who underwent transoral resection +/- adjuvant therapy at a single center between 1996 and 2018. Twenty patients (4.9%) developed SPM of the UADT, nine (2.2%) occurring in the oropharynx. Median time to diagnosis was 59.5 months (0-173 months). Risk of SPM was lower for patients receiving adjuvant radiation (aHR: 0.25, 95%CI: 0.08-0.78). There was no difference in overall or disease-free survival between those with and without SPM. The rate of SPM among patients with HPV-positive OPSCC is lower than reported rates among HPV-negative OPSCC. To date, this is the largest study evaluating SPM in patients with surgically treated HPV-positive OPSCC.
Sections du résumé
BACKGROUND
Little data exists regarding the incidence of oropharyngeal and upper aerodigestive tract (UADT) second primary malignancies (SPM) among human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here we evaluate SPM rates among patients with HPV-related OPSCC.
METHODS
A retrospective cohort study of 412 patients with HPV-related OPSCC who underwent transoral resection +/- adjuvant therapy at a single center between 1996 and 2018.
RESULTS
Twenty patients (4.9%) developed SPM of the UADT, nine (2.2%) occurring in the oropharynx. Median time to diagnosis was 59.5 months (0-173 months). Risk of SPM was lower for patients receiving adjuvant radiation (aHR: 0.25, 95%CI: 0.08-0.78). There was no difference in overall or disease-free survival between those with and without SPM.
CONCLUSION
The rate of SPM among patients with HPV-positive OPSCC is lower than reported rates among HPV-negative OPSCC. To date, this is the largest study evaluating SPM in patients with surgically treated HPV-positive OPSCC.
Identifiants
pubmed: 35175648
doi: 10.1002/hed.27002
pmc: PMC9112335
mid: NIHMS1803620
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1069-1078Subventions
Organisme : NIDCD NIH HHS
ID : T32 DC000022
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR002344
Pays : United States
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Laryngoscope. 2019 May;129(5):1141-1149
pubmed: 30152175
Head Neck. 1999 May;21(3):204-10
pubmed: 10208662
J Clin Oncol. 2006 Feb 10;24(5):736-47
pubmed: 16401683
J Clin Oncol. 2006 Dec 20;24(36):5630-6
pubmed: 17179101
Oral Oncol. 2017 Jan;64:37-43
pubmed: 28024722
J Otolaryngol Head Neck Surg. 2013 May 29;42:36
pubmed: 23718873
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Otolaryngol Head Neck Surg. 2018 Mar;158(3):479-483
pubmed: 29160154
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):276-83
pubmed: 20950953
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Adv Ther. 2018 Feb;35(2):153-160
pubmed: 29396681
Otolaryngol Head Neck Surg. 2021 Apr;164(4):733-740
pubmed: 32928026
Int J Cancer. 2008 Nov 15;123(10):2390-6
pubmed: 18729183
JAMA. 2004 May 26;291(20):2441-7
pubmed: 15161894
Head Neck. 2017 Nov;39(11):2224-2231
pubmed: 28782298
Oral Oncol. 2020 Jan;100:104475
pubmed: 31765835
Head Neck. 2013 Jun;35(6):794-9
pubmed: 22711172
Laryngoscope. 2011 Jun;121(6):1194-201
pubmed: 21495044
Cancer. 2013 May 15;119(10):1832-7
pubmed: 23423883
JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1099-108
pubmed: 23576186
Head Neck. 2016 Apr;38 Suppl 1:E873-83
pubmed: 25966421
J Clin Oncol. 2011 Feb 20;29(6):739-46
pubmed: 21189382
Otolaryngol Head Neck Surg. 2003 Jul;129(1):65-70
pubmed: 12869919
Cancer. 1953 Sep;6(5):963-8
pubmed: 13094644
BMC Cancer. 2013 May 01;13:220
pubmed: 23634887
J Cancer Res Clin Oncol. 2014 Jun;140(6):1011-9
pubmed: 24615330
Clin Otolaryngol. 2018 Feb;43(1):1-6
pubmed: 28891195
Head Neck. 2015 Nov;37(11):1603-11
pubmed: 24931847